SGMT News

Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences

Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne

Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne USA - English APAC - English APAC - Traditional Chinese

Biotech Veteran and Virologist Joins CancerVax as Senior Scientific Advisor

Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference

Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination

Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program

Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration

Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment USA - English APAC - Traditional Chinese APAC - English